Heart Health and Weight Management: The Unique Benefits of Wegovy for Women

Boosting Heart Health & Weight Loss: Why Women Are Turning to Wegovy

February is the British Heart Foundation’s Heart Month - and it's the perfect time to discuss the critical connection between heart health and weight management. If you’re navigating your weight loss journey while prioritising your cardiovascular well-being, you’re not alone. The good news? Wegovy (Semaglutide) is the only GLP-1 medication approved to reduce the risk of serious heart conditions in overweight and obese individuals. If you’re considering the weight management programme at HANX, let’s explore why Wegovy can be a game-changer for women.

The Heart of the Matter: Wegovy’s Groundbreaking Benefits

Since July 2024, Wegovy has been the first and only medication of its kind approved to lower the risk of major heart complications in adults managing their weight. The SELECT trial, published in the New England Journal of Medicine, studied over 17,000 adults with overweight or obesity and pre-existing heart disease. The results? Wegovy reduced the risk of heart attacks, strokes, and cardiovascular-related deaths by 20% compared to a placebo.

Key Benefits of Wegovy for Heart Health:

• 20% lower risk of major cardiovascular events (heart attacks, strokes, or heart-related deaths)

• Improved blood pressure levels

• Better cholesterol management

• Sustainable weight loss, reducing strain on the heart

These benefits appeared within the first year of treatment, meaning that while you focus on your weight management goals, Wegovy is already working to protect your heart. Compared to other medications like Mounjaro (tirzepatide) - which is effective for weight loss but lacks this specific heart-health approval - Wegovy is a top choice for women prioritising cardiovascular well-being.

Why This Matters for Women’s Heart Health

Heart disease is the leading cause of death among women, with over 3.6 million women in the UK currently living with a heart or circulatory disease. Yet, it is often underdiagnosed and undertreated. Women face unique cardiovascular challenges, including:

• Different heart attack symptoms than men (e.g., jaw pain, nausea, or fatigue instead of classic chest pain)

• Hormonal changes during menopause, which increase cardiovascular risk

• Greater difficulty managing weight during perimenopause and menopause

Is Wegovy Right for You?

Considering Wegovy for weight loss and heart health? It could be an ideal option if:

• Heart disease runs in your family

• You’re approaching or going through menopause

• You have multiple health concerns and need an effective, dual-benefit solution

• You want a weight management plan that actively supports heart health

Looking Ahead: A Brighter Future for Women’s Health

We spoke to Dr. Sarah Welsh, Co-Founder of HANX regarding the unique benefits of Wegovy: 

“In my time working in bariatric surgery, these types of medications were not even available. These groundbreaking medications like Wegovy are redefining how we approach weight loss and heart disease prevention. We’re now offering Wegovy as part of the weight management programme at HANX to give our customers the tools they need to effectively manage their weight and heart health.”

Start Your Journey Today

Want to explore how Wegovy can help you achieve your weight and heart health goals? Start your consultation today!

Want more? 

• Learn why science backs Semaglutide for weight management here.

• Curious about the pricing on the HANX weight management programme? See our transparent pricing guide.